Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care. After a 46% decrease in new patient accruals, and a 24% decrease in newly activated trials between March and May 2020, a bounceback was seen in 2021. The findings suggest ways of improving the running of clinical trials and improving patients access to them worldwide.